Atopic dermatitis is increasing in prevalence and currently affects 15-30% of children in urban areas. Immune dysregulation and an impaired epidermal barrier are important factors in the ...
Credit: Arcutis Biotherapeutics, Inc./GlobeNewswire. Arcutis Biotherapeutics‘ subsidiary, Arcutis Canada, has received Health Canada’s approval for ZORYVE (roflumilast) topical foam 0.3%, to treat ...
TORONTO, Oct. 21, 2024 /CNW/ - Arcutis Canada Inc., a commercial-stage company focused on delivering meaningful innovations in immuno-dermatology, is pleased to announce that Health Canada has ...
WESTLAKE VILLAGE, Calif. - Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a biopharmaceutical company specializing in immuno-dermatology, announced the regulatory approval by Health Canada for ZORYVE ...